BRIGHT EVIDENCE PACK / Experimental
A new lead against resistant bacteria.
Scientists identified abaucin, a compound active against Acinetobacter baumannii, with help from deep learning.
Canonical Bright record · JSON evidence pack · Key-facts embed
Dates and assessment
- Source published
- 2023-05-25
- Bright published
- 2026-09-05
- Substantive update
- None recorded
- Evidence state
- Experimental
- Independent verification
- Not established by this source review
- Last source review
- 2026-09-05
The claim in context
The human problem
Antibiotic resistance narrows the options for treating infections.
The prior constraint
Screening compounds experimentally is resource intensive.
AI’s actual role
A model prioritized compounds for laboratory testing.
The documented result
Abaucin showed activity in experiments, including a mouse wound infection model.
Why it may matter
A possible starting point for developing a narrow-spectrum antibiotic.
Limitations
- Preclinical evidence. Human safety and efficacy are not established.
Original evidence
Attribution
Credit Bright AI Future and link the canonical Bright record.
- Link to the canonical Bright record.
- Keep material limitations with the claim they qualify.
- Link to the original evidence when repeating a substantive claim.
- Do not describe a source check or organization-reported result as independent verification.
Linked source material, quotations, trademarks and media remain subject to their owners’ terms. No reuse right is granted for third-party media.